CoChat

Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review

Open access
Xie, Zeyu, Hu, Jia, Gu, Hangye, Li, Mengting, Chen, Jisheng · 2023 · Frontiers in Endocrinology

The DOI matches its Crossref record; 61 of the 63 references it cites were found in a registry or an index.

Abstract

Purpose: This study aimed to perform a network meta-analysis to objectively evaluate the efficacy and safety of 10 Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in combination with metformin that is approved for use worldwide in patients with type 2 diabetes and to provide evidence-based support and reference for the selection of clinical treatment. Methods: Three databases (PubMed, Embase, and Cochrane Library) were searched from their respective inception until September 30, 2022. Only randomized controlled trials comparing the efficacy and safety of GLP-1RAs for treating type 2 diabetes (T2D) were included. The 10 GLP-1RAs are exenatide (including exenatide twice daily and once weekly), liraglutide, lixisenatide, dulaglutide, PEX168, semaglutide (subcutaneous and oral semaglutide), tirzepatide and albiglutide. Results: 34 RCTs with 10 GLP-1RAs and 12993 patients were included in the Network Meta-Analysis (NMA). According to the NMA, tirzepatide 15 mg, semaglutide 1.0 mg, PEX168-200μg, oral semaglutide 14 and dulaglutide 1.5 mg reduced HbA1c by -2.23%, -1.57%, -1.12%, -1.10%, -1.09% and body weight by -11.33 kg, -5.99 kg, +0.40 kg, -3.95 kg, -1.87 kg, respectively. There was no significant difference in the rate of adverse events for tirzepatide 15 mg, oral-semaglutide 14 mg, and semaglutide 1.0 mg. PEX168-200μg, tirzepatide 15mg, and oral semaglutide 14mg had Surface Under the Cumulative Ranking (SUCRA) values greater than placebo, and only tirzepatide 15mg and oral semaglutide 14mg were significantly different from placebo in the rate of serious adverse events. All GLP-1RA did not lead to increased incidence of hypoglycemia. Albiglutide 30mg and semaglutide 1.0mg significantly differed from placebo in Adverse Event (AE) withdrawal. Finally, the sensitivity analysis and publication bias analysis results indicate that the study results are reliable. Conclusion: This study’s results showed that GLP-1RAs were effective in lowering HbA1c and reducing body weight without increased incidence of hypoglycemic reactions. In addition, this study may provide reference and evidence-based medical evidence for clinicians to select GLP-1RAs in patients with T2D and high body mass index (BMI). Based on the NMA results, tirzepatide 15mg and semaglutide 1.0mg may be preferred.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2023.1244432

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow chart of the study selection process.
Figure 1 Flow chart of the study selection process.CC BY · PubMed Central
Figure 2 Risk of bias assessment plots.
Figure 2 Risk of bias assessment plots.CC BY · PubMed Central
Figure 3 Risk of bias summary plots.
Figure 3 Risk of bias summary plots.CC BY · PubMed Central
Figure 4 Network plot. (A) (Decreased HbA1c), (B) (Weight loss), (C) (The rate of adverse events), (D) (The rate of serious adverse events), (E) (Hypoglycemic events); (F) (AE withdrawal); (Note: Each node represents a specific intervention, the size of the nodes corresponds to the number of participants assigned to each treatment).
Figure 4 Network plot. (A) (Decreased HbA1c), (B) (Weight loss), (C) (The rate of adverse events), (D) (The rate of serious adverse events), (E) (Hypoglycemic events); (F) (AE withdrawal); (Note: Each node represents a specific intervention, the size of the nodes corresponds to the number of participants assigned to each treatment).CC BY · PubMed Central
Figure 5 The ranking of GLP-1RA based on cumulative probability plots and SUCRA. (A) (Decreased HbA1c), (B) (Weight loss), (C) (The rate of adverse events), (D) (The rate of serious adverse events), (E) (Hypoglycemic events), (F) (AE withdrawal).
Figure 5 The ranking of GLP-1RA based on cumulative probability plots and SUCRA. (A) (Decreased HbA1c), (B) (Weight loss), (C) (The rate of adverse events), (D) (The rate of serious adverse events), (E) (Hypoglycemic events), (F) (AE withdrawal).CC BY · PubMed Central
Figure 6 The funnel plots for efficacy and safety. (A) (Decreased HbA1c), (B) (Weight loss), (C) (The rate of adverse events), (D) (The rate of serious adverse events), (E) (Hypoglycemic events), (F) (AE withdrawal), (Note: A: Placebo; B: Albi30mg; C: PEX168-200μg; D: Lixisenatide20μg; E: Tirze15mg; F: Dulaglutide1.5mg; G: Oralsema14mg; H: Sema1.0mg; I: Lira1.8mg; J: Weekly-Exenatide2.0mg; K: Daily-Exenatide10μg).
Figure 6 The funnel plots for efficacy and safety. (A) (Decreased HbA1c), (B) (Weight loss), (C) (The rate of adverse events), (D) (The rate of serious adverse events), (E) (Hypoglycemic events), (F) (AE withdrawal), (Note: A: Placebo; B: Albi30mg; C: PEX168-200μg; D: Lixisenatide20μg; E: Tirze15mg; F: Dulaglutide1.5mg; G: Oralsema14mg; H: Sema1.0mg; I: Lira1.8mg; J: Weekly-Exenatide2.0mg; K: Daily-Exenatide10μg).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Research works printed but not linked: 5

  1. 2021, IDF Diabetes Atlas
  2. 2021, Chinese guidelines for the prevention and treatment of type 2 diabetes mellitus (2020 edition), Int J Endocrinol Metab, 41, 482, 10.19538/j.nk2021080106 · doi:10.19538/j.nk2021080106
  3. Jing, 2020, Research progress of glucagon-like peptide-1 receptor agonists in cardiovascular complications of type 2 diabetes mellitus, Modern Diagnosis Ther, 31, 3041
  4. Yanlan, 2022, Cardiovascular benefit of SGLT-2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes: a systematic review and reticulated Meta-analysis, J Pharm Pract, 40
  5. Chang, 2021, Recent research progress on the evidence and mechanism of cardiovascular benefit of SGLT2 inhibitors in type 2 diabetes mellitus population, Modern Med Health, 37

Metadata

Authors
Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J.
Affiliations
First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
Corresponding author
Chen, Jisheng
Venue
Frontiers in Endocrinology
Published
2023-08-28
Volume
14
Pages
1244432-1244432
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4386220010
Cited by
47
References
63
Citations by year
2026: 11 · 2025: 20 · 2024: 15 · 2023: 1
FWCI
1.69
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, type 2 diabetes, metformin add-on therapy, tirzepatide, semaglutide, dulaglutide, exenatide, liraglutide, lixisenatide, albiglutide, HbA1c, body weight, adverse events, treatment efficacy
MeSH terms
Glucagon-Like Peptide-1 Receptor, Exenatide, Body Weight, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Metformin, Peptides, Polyethylene Glycols

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review. https://app.cochat.ai/papers/10.3389/fendo.2023.1244432
The paper
Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023). Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1244432

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.